

ABSTRACT OF THE DISCLOSURE

The present invention features mutated forms of PPAR ligand binding domain polypeptides that: (1) bind a partial PPAR agonist; and (2) is bound or activated by a full PPAR agonist to a lesser extent than the wild-type receptor. The mutated ligand binding domain 5 contains an amino acid sequence wherein one or more interactions that preferentially (preferably solely) occurs between a full PPAR agonist and the AF-2 domain of a wild-type PPAR are modified. Preferably, the mutated ligand binding domain is selectively bound or activated by a partial PPAR agonist.